NCT03911973 - Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 17, 2019

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions

TNBC - Triple-Negative Breast Cancer

Interventions

DRUG

Gedatolisib

Gedatolisib, 150-180MG IV

DRUG

Talazoparib

.75-1.00mg

Trial Locations (5)

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

University of Iowa Hospital and Clinics, Iowa City

University of Wisconsin, Madison

Northwestern University Feinberg School of Medicine, Chicago

University of Illinois Cancer Center, Chicago